Sharechat Logo

AFT gains Australian registration for intravenous Maxigesic

Wednesday 24th July 2019

Text too small?

AFT Pharmaceuticals says it has successfully registered the intravenous form of its Maxigesic medication with Australia’s Therapeutic Goods Administration.

The intravenous product contains 1,000 milligrams of paracetamol and 300mg of ibuprofen in a 100 millilitre solution.

The company says it expects to sell the product in Australia during the year ending March 2020 and the registration “clears the way for regulatory filings in a number of other territories including but not limited to Mexico, South East Asia, Korea and the Middle East, all of which rely upon registration by key global reference regulators such as the TGA in Australia.”

AFT says the product is designed for post-operative pain relief for patients who can’t take oral pain relief.

(BusinessDesk)



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

PEB - Chair to Seek Re-Election; Director Nominations
Devon Funds Morning Note - 16 June 2025
TRU - Key Markets Update
THL receives unsolicited non-binding offer
June 16th Morning Report
CHATHAM ANNOUNCES NON-BROKERED PRIVATE PLACEMENT
Radius Care Upgrades FY26 Outlook
June 13th Morning Report
June 12th Morning Report
PGW Governance Update